TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy

NCT04084886 | Unknown

• 1 other identifier: TCF7L2 in Diabetic nephropathy
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

1. 1.To study genotypic distribution of the TCF7L2 gene polymorphism in Diabetic nephropathy.
2. 2.To assess level of AGEs and Insulin in patients with Diabetic nephropathy.
3. 3.To study correlation between polymorphism of the TCF7L2 gene, AGEs, Insulin and clinical characteristics in patients with diabetic nephropathy

Conditions

Diabetic Nephropathies

Outcome Measures

Primary Outcomes (2)

• value of the odds ratio associated with the relationship between a polymorphism TCF7L2 gene and the occurrence of diabetic nephropathy

  find a link between genetic polymorphism of TCF7L2 and the risk of developing nephropathy in diabetic patients. Nephropathy is defined Albumin/creatinine ratio \> 30 mg/gm creat.

  one year

• Number of patients with genotype TCF7L2 by PCR

  the prevalence of TCF7L2, in the diabetic patient, and compared to the values found in the general population. the TCF7L2 genes will be evaluated by PCR-RFLP

  5 years

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

* 60 diabetic patients: Diagnosis of DM was based on the American Diabetes Association Criteria: -The diabetic patients will be classified into 2 subgroups: * 30 Diabetic patients without any microvascular or macrovascular complications. * 30 Diabetic patients with pure nephropathy not having other microvascular or macrovascular complications. * 20 patients diagnosed as prediabetes: * Beside 20 Apparent healthy subjects as control group.

You may qualify if:

• diabetic nephropathy
• clinical diagnosis of prediabetes
• Type 2 diabetic patients

You may not qualify if:

• cardiovascular disease
• diabetic neuropathy
• diabetic retinopathy

Sponsors & Collaborators

• Assiut University: lead

Related Publications (2)

• Gawandi S, Gangawane S, Chakrabarti A, Kedare S, Bantwal K, Wadhe V, Kulkarni A, Kulkarni S, Rajan MGR. A Study of Microalbuminuria (MAU) and Advanced Glycation End Products (AGEs) Levels in Diabetic and Hypertensive Subjects. Indian J Clin Biochem. 2018 Jan;33(1):81-85. doi: 10.1007/s12291-017-0638-5. Epub 2017 Feb 1.

  PMID: 29371774 BACKGROUND

• Adamska E, Kretowski A, Goscik J, Citko A, Bauer W, Waszczeniuk M, Maliszewska K, Paczkowska-Abdulsalam M, Niemira M, Szczerbinski L, Ciborowski M, Gorska M. The type 2 diabetes susceptibility TCF7L2 gene variants affect postprandial glucose and fat utilization in non-diabetic subjects. Diabetes Metab. 2018 Sep;44(4):379-382. doi: 10.1016/j.diabet.2017.05.001. Epub 2017 May 31. No abstract available.

  PMID: 28579156 BACKGROUND

MeSH Terms

Conditions

Diabetic Nephropathies

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases

Central Study Contacts

Ghadeer Abdelrazzak

CONTACT

01011676458; ghadeer.razzak111@hotmail.com

Madeeha Younis

CONTACT

01009344150; madeehayb@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant lecturer

Study Record Dates

• First Submitted: September 3, 2019
• First Posted: September 10, 2019
• Study Start: September 1, 2019
• Primary Completion: September 1, 2020
• Study Completion: October 1, 2020
• Last Updated: September 10, 2019

Record last verified: 2019-09